Discover 476 paid clinical trials in Grand Rapids, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 476
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
for
Recurrent Langerhans Cell Histiocytosis,
Location: Grand Rapids MI, Kalamazoo MI, Milwaukee WI, Chicago IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 22
Code: NCT05828069
Phase2, Recruiting
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
for
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Location: Grand Rapids MI, Columbus OH, Valhalla NY,
Sponsor: New York Medical College
Sex: All
Age: 1 - 31
Code: NCT03719105
Early_phase1, Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
for
Stage II Nasopharyngeal Carcinoma AJCC v8,
Location: Grand Rapids MI, Milwaukee WI, Chicago IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 21
Code: NCT06064097
Phase2, Recruiting
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
for
Rheumatic Joint Disease
Location: Grand Rapids MI, Ann Arbor MI, Wauwatosa WI, Chicago IL,
Sponsor: Duke University
Sex: All
Age: 0 - 21
Code: NCT02418442
Recruiting
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
for
B-cell Acute Lymphoblastic Leukemia
Location: Grand Rapids MI, Indianapolis IN, Buffalo NY,
Location: Grand Rapids MI, Kalamazoo MI, Ann Arbor MI,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase2, Recruiting
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
for
Infusion Reactions
Location: Grand Rapids MI, Milwaukee WI, Chicago IL, Detroit MI,
Sponsor: New York Blood Center
Sex: All
Age: 0+
Code: NCT01656603
Phase2, Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
for
Childhood Medulloblastoma
Location: Grand Rapids MI, Ann Arbor MI, Milwaukee WI, Chicago IL,
Sponsor: Children's Oncology Group
Sex: All
Age: 4 - 21
Code: NCT05382338
Phase3, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Location: Grand Rapids MI, Kalamazoo MI, Ann Arbor MI, Chicago IL,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 22
Code: NCT04726241
Phase1, Phase2, Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: Grand Rapids MI, Kalamazoo MI, Ann Arbor MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 30
Code: NCT06172296
Phase3, Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Grand Rapids MI, Kalamazoo MI, Ann Arbor MI,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT04293562
Phase3, Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for
Acute Leukemia of Ambiguous Lineage,
Location: Grand Rapids MI, Kalamazoo MI, Ann Arbor MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 1
Code: NCT06317662
Phase2, Recruiting
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
for
Cystic Fibrosis
Location: Grand Rapids MI, Ann Arbor MI, Chicago IL, Detroit MI,
Sponsor: Nicole Hamblett
Sex: All
Age: 12+
Code: NCT06504589
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma